(ICHR) Ichor Holdings - Overview
Stock: Gas Delivery, Chemical Delivery, Precision Components, Surface Treatment
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 101% |
| Relative Tail Risk | -13.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.43 |
| Alpha | -36.19 |
| Character TTM | |
|---|---|
| Beta | 2.747 |
| Beta Downside | 2.248 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.09% |
| CAGR/Max DD | -0.04 |
Description: ICHR Ichor Holdings December 26, 2025
Ichor Holdings Ltd (NASDAQ:ICHR) designs, engineers and manufactures fluid-delivery subsystems and precision components for semiconductor capital equipment. Its product portfolio includes gas delivery systems for etch and deposition, chemical delivery modules for CMP, electroplating and cleaning, as well as specialty machined parts, weldments and surface-treatment technologies, sold primarily to equipment OEMs in Japan.
Key industry metrics that shape Ichor’s outlook include the global semiconductor equipment market, which the SEMI forecast expects to grow at a 7-8% CAGR through 2027, driven by rising demand for advanced nodes and 3-D packaging. Ichor’s revenue has shown a compound annual growth rate of roughly 12% over the past three fiscal years, with gross margins hovering near 38%-a level that reflects its high-mix, high-value product mix. Capital-expenditure cycles in the semiconductor sector, particularly the “boom-bust” pattern tied to inventory corrections, remain the dominant driver of Ichor’s order flow; a recent uptick in wafer-fab capex in East Asia could translate into a near-term lift for the company.
For a deeper, data-driven view of Ichor’s valuation and risk profile, you might explore the analytical tools on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -40.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA -7.35 > 1.0 |
| NWC/Revenue: 29.97% < 20% (prev 39.56%; Δ -9.59% < -1%) |
| CFO/TA 0.02 > 3% & CFO 18.2m > Net Income -40.8m |
| Net Debt (70.6m) to EBITDA (2.61m): 27.06 < 3 |
| Current Ratio: 3.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (34.3m) vs 12m ago 1.92% < -2% |
| Gross Margin: 11.58% > 18% (prev 0.12%; Δ 1146 % > 0.5%) |
| Asset Turnover: 98.57% > 50% (prev 83.95%; Δ 14.62% > 0%) |
| Interest Coverage Ratio: -4.29 > 6 (EBITDA TTM 2.61m / Interest Expense TTM 6.61m) |
Altman Z'' 2.78
| A: 0.30 (Total Current Assets 424.9m - Total Current Liabilities 138.0m) / Total Assets 966.6m |
| B: 0.15 (Retained Earnings 147.0m / Total Assets 966.6m) |
| C: -0.03 (EBIT TTM -28.3m / Avg Total Assets 971.2m) |
| D: 0.51 (Book Value of Equity 147.0m / Total Liabilities 290.4m) |
| Altman-Z'' Score: 2.78 = A |
Beneish M -3.08
| DSRI: 0.86 (Receivables 84.4m/84.2m, Revenue 957.3m/819.2m) |
| GMI: 1.02 (GM 11.58% / 11.80%) |
| AQI: 0.98 (AQ_t 0.41 / AQ_t-1 0.41) |
| SGI: 1.17 (Revenue 957.3m / 819.2m) |
| TATA: -0.06 (NI -40.8m - CFO 18.2m) / TA 966.6m) |
| Beneish M-Score: -3.08 (Cap -4..+1) = AA |
What is the price of ICHR shares?
Over the past week, the price has changed by +5.97%, over one month by +41.07%, over three months by +113.06% and over the past year by -1.08%.
Is ICHR a buy, sell or hold?
- StrongBuy: 5
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ICHR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 30.1 | -6.3% |
| Analysts Target Price | 30.1 | -6.3% |
| ValueRay Target Price | 36 | 12% |
ICHR Fundamental Data Overview February 07, 2026
P/S = 1.0243
P/B = 1.4236
P/EG = 0.5194
Revenue TTM = 957.3m USD
EBIT TTM = -28.3m USD
EBITDA TTM = 2.61m USD
Long Term Debt = 117.2m USD (from longTermDebt, last quarter)
Short Term Debt = 17.6m USD (from shortTermDebt, last quarter)
Debt = 163.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 70.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.05b USD (980.6m + Debt 163.1m - CCE 92.5m)
Interest Coverage Ratio = -4.29 (Ebit TTM -28.3m / Interest Expense TTM 6.61m)
EV/FCF = -55.07x (Enterprise Value 1.05b / FCF TTM -19.1m)
FCF Yield = -1.82% (FCF TTM -19.1m / Enterprise Value 1.05b)
FCF Margin = -1.99% (FCF TTM -19.1m / Revenue TTM 957.3m)
Net Margin = -4.26% (Net Income TTM -40.8m / Revenue TTM 957.3m)
Gross Margin = 11.58% ((Revenue TTM 957.3m - Cost of Revenue TTM 846.5m) / Revenue TTM)
Gross Margin QoQ = 11.76% (prev 11.32%)
Tobins Q-Ratio = 1.09 (Enterprise Value 1.05b / Total Assets 966.6m)
Interest Expense / Debt = 1.01% (Interest Expense 1.65m / Debt 163.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -22.4m (EBIT -28.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.08 (Total Current Assets 424.9m / Total Current Liabilities 138.0m)
Debt / Equity = 0.24 (Debt 163.1m / totalStockholderEquity, last quarter 676.2m)
Debt / EBITDA = 27.06 (Net Debt 70.6m / EBITDA 2.61m)
Debt / FCF = -3.70 (negative FCF - burning cash) (Net Debt 70.6m / FCF TTM -19.1m)
Total Stockholder Equity = 692.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.20% (Net Income -40.8m / Total Assets 966.6m)
RoE = -5.89% (Net Income TTM -40.8m / Total Stockholder Equity 692.3m)
RoCE = -3.50% (EBIT -28.3m / Capital Employed (Equity 692.3m + L.T.Debt 117.2m))
RoIC = -2.74% (negative operating profit) (NOPAT -22.4m / Invested Capital 818.2m)
WACC = 13.87% (E(980.6m)/V(1.14b) * Re(16.04%) + D(163.1m)/V(1.14b) * Rd(1.01%) * (1-Tc(0.21)))
Discount Rate = 16.04% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 8.08%
Fair Price DCF = unknown (Cash Flow -19.1m)
EPS Correlation: -74.53 | EPS CAGR: -42.77% | SUE: 0.79 | # QB: 0
Revenue Correlation: -52.70 | Revenue CAGR: -4.75% | SUE: 1.39 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.06 | Chg30d=+0.008 | Revisions Net=+2 | Analysts=7
EPS next Year (2026-12-31): EPS=0.79 | Chg30d=+0.059 | Revisions Net=+3 | Growth EPS=+363.9% | Growth Revenue=+6.5%